Abstract 1876P
Background
Societal beliefs about cancer can impact how patients perceive their disease generating cancer stigma (CS) with risk of emotional distress especially in Arab countries where cancer remains a taboo. This study aimed to evaluate aspects of CS according to Tunisian cancer patients, explore risk factors and describe the impact on mental health.
Methods
The study was a cross-sectional questionnaire-based study, conducted between February and April 2023, including 100 patients treated for cancer regardless of gender, type or stage. We developed the questionnaire by adapting items from the “Cancer stigma scale” using questions grouped in three domains: impossibility of recovery, stereotypes of cancer patients and experience of social discrimination. Depression and anxiety were evaluated by using the “Hospital Anxiety and Depression Scale”.
Results
Median age was 50 years old, 75% of patients were women. On average, patients were surveyed 20.48 months after diagnosis. Patients reported at least one form of CS in 57% of cases. They believed in the impossibility of recovery after cancer experience in 47% of cases. Forty percent of patients held stereotypical views of themselves: 48% endorsed that cancer patients would have a difficult time having sexual intimacy which was the item with the highest mean (2.45) among all questions. Thirty four percent of patients reported social discrimination on grounds of cancer: by family/spouse in 31%, at the workplace in 15% and by friends/neighbors in 13% of cases. Cancer stigma was significantly more perceived by patients with low socioeconomic status (OR= 3.74 [1.42-9.82]), living in rural areas (OR=26 [3.38-205] and with advanced stage disease (OR=4.2 [1.67-10.5]). Forty percent of patients reported significant depressive symptoms and 47% significant anxiety symptoms. Patients who experienced CS were 4.27 times more likely to have depression (p <0.001) and 3.57 times more probably to be anxious (p <0.001) than patients with positive attitudes.
Conclusions
Despite increased awareness, cancer patients had high levels of CS with negative impact on mental health. These results ring the alarm bell to change societal beliefs and to help patients perceive “better” their disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05